Trade Alnylam Pharmaceuticals, Inc. - ALNY CFD
Add to favourite- Summary
- Historical Data
| Spread | 1.88 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.7 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 248.69 |
| Open | 245.22 |
| 1-Year Change | 48.53% |
| Day's Range | 245.22 - 250.17 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 20, 2024 | 248.69 | 14.73 | 6.30% | 233.96 | 248.86 | 232.39 |
| Nov 19, 2024 | 233.33 | 2.15 | 0.93% | 231.18 | 235.57 | 230.20 |
| Nov 18, 2024 | 232.09 | -2.81 | -1.20% | 234.90 | 239.66 | 229.61 |
| Nov 15, 2024 | 235.36 | -17.68 | -6.99% | 253.04 | 253.64 | 234.13 |
| Nov 14, 2024 | 257.74 | -1.81 | -0.70% | 259.55 | 262.42 | 256.70 |
| Nov 13, 2024 | 264.41 | -3.48 | -1.30% | 267.89 | 269.87 | 263.50 |
| Nov 12, 2024 | 267.84 | -0.12 | -0.04% | 267.96 | 270.41 | 263.83 |
| Nov 11, 2024 | 278.43 | 3.32 | 1.21% | 275.11 | 285.65 | 275.11 |
| Nov 8, 2024 | 276.46 | 6.27 | 2.32% | 270.19 | 279.44 | 269.90 |
| Nov 7, 2024 | 271.35 | 1.77 | 0.66% | 269.58 | 273.77 | 269.33 |
| Nov 6, 2024 | 271.96 | 5.55 | 2.08% | 266.41 | 277.75 | 265.47 |
| Nov 5, 2024 | 264.14 | -3.76 | -1.40% | 267.90 | 268.52 | 263.17 |
| Nov 4, 2024 | 269.85 | 1.19 | 0.44% | 268.66 | 272.53 | 262.32 |
| Nov 1, 2024 | 272.50 | 9.33 | 3.55% | 263.17 | 273.57 | 263.17 |
| Oct 31, 2024 | 266.53 | -5.32 | -1.96% | 271.85 | 274.31 | 263.20 |
| Oct 30, 2024 | 281.31 | -2.59 | -0.91% | 283.90 | 287.40 | 280.88 |
| Oct 29, 2024 | 284.64 | 0.43 | 0.15% | 284.21 | 286.36 | 282.13 |
| Oct 28, 2024 | 286.75 | 1.18 | 0.41% | 285.57 | 290.71 | 285.54 |
| Oct 25, 2024 | 284.79 | -7.25 | -2.48% | 292.04 | 293.40 | 283.73 |
| Oct 24, 2024 | 293.56 | 2.04 | 0.70% | 291.52 | 300.98 | 291.33 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Alnylam Company profile
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia. Its clinical programs also include ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR, which is in the Phase I clinical trial for the treatment of various forms of ATTR amyloidosis; Lumasiran (ALN-GO1) that is in Phase I/II clinical trial for the treatment of primary hyperoxaluria type 1; and Cemdisiran (ALN-CC5), which is in the Phase II clinical trial for the treatment of complement-mediated diseases. The company has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.| Industry: | Biotechnology & Medical Research (NEC) |
675 W Kendall St
CAMBRIDGE
MASSACHUSETTS 02142-1168
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com